trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

HER2-positive breast cancer cases account for 15% to 20% of all new breast cancer cases.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
5 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that HER2-positive breast cancer cases account for 15% to 20% of all new breast cancer cases?

Yes. Multiple medical sources and literature reviews confirm that HER2-positive breast cancer accounts for approximately 15% to 25% of all breast cancer cases.

Verdict: SUPPORTED · 5 sources for, 0 against · Last checked

The analysis

Judged against statistical and reference sources.

Evidence for · 5
PLOS (all journals): Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis
It states that HER2 amplification occurs in 10%-35% of human breast cancers, which encompasses 15% to 20%.
Get citation
PLOS (all journals): Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. (n.d.). PLOS (all journals). https://doi.org/10.1371/journal.pone.0127404

See more details
More for · 4
ClinicalTrials.gov: Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer
It explicitly states that HER2-positive breast cancer accounts for about 15-20% of all breast cancer cases.
Get citation
ClinicalTrials.gov: Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06492447

Semantic Scholar peS2o: Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
It explicitly states that the HER2-positive subtype accounts for 15-20% of all breast cancers.
Get citation
Semantic Scholar peS2o: Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer. (n.d.). Semantic Scholar peS2o. https://www.mdpi.com/2072-6694/11/5/646/pdf

ClinicalTrials.gov: A Non-inferior, Randomized Controlled Phase III Clinical Study Comparing the Efficacy of TCbHPand ECHP-THP in Neoadjuvant Treatment of Operable HER2-positive Breast Cancer
It notes that HER2-overexpressing breast cancer accounts for about 20% to 30%, largely overlapping with the claim.
Get citation
ClinicalTrials.gov: A Non-inferior, Randomized Controlled Phase III Clinical Study Comparing the Efficacy of TCbHPand ECHP-THP in Neoadjuvant Treatment of Operable HER2-positive Breast Cancer. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05474690

Semantic Scholar peS2o: Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
It states that HER2-positive breast cancer accounts for approximately 25% of cases, supporting the general range.
Get citation
Semantic Scholar peS2o: Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. (n.d.). Semantic Scholar peS2o. https://www.nature.com/articles/s41523-020-0153-3.pdf

What does the evidence say?

Judged against statistical and reference sources.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work